Next Article in Journal
Targeting Cytokines, Pathogen-Associated Molecular Patterns, and Damage-Associated Molecular Patterns in Sepsis via Blood Purification
Next Article in Special Issue
Serum-Derived Neuronal Exosomal miRNAs as Biomarkers of Acute Severe Stress
Previous Article in Journal
The Role of Antimicrobial Peptides in Preterm Birth
Previous Article in Special Issue
Effects of Normal Synovial Fluid and Interferon Gamma on Chondrogenic Capability and Immunomodulatory Potential Respectively on Equine Mesenchymal Stem Cells
Review

Cellular Therapy for the Treatment of Paediatric Respiratory Disease

1
College of Medicine, Nursing & Health Sciences, National University of Ireland, H91 TK33 Galway, Ireland
2
Research and Development, Science and Emerging Technologies, Aerogen Limited, Galway Business Park, H91 HE94 Galway, Ireland
3
School of Pharmacy and Pharmaceutical Sciences, Trinity College, D02 PN40 Dublin, Ireland
4
School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland
*
Author to whom correspondence should be addressed.
Academic Editor: Marcin Majka
Int. J. Mol. Sci. 2021, 22(16), 8906; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22168906
Received: 27 July 2021 / Revised: 12 August 2021 / Accepted: 13 August 2021 / Published: 18 August 2021
(This article belongs to the Special Issue Stem Cells—from Bench to Bedside 2021)
Respiratory disease is the leading cause of death in children under the age of 5 years old. Currently available treatments for paediatric respiratory diseases including bronchopulmonary dysplasia, asthma, cystic fibrosis and interstitial lung disease may ameliorate symptoms but do not offer a cure. Cellular therapy may offer a potential cure for these diseases, preventing disease progression into adulthood. Induced pluripotent stem cells, mesenchymal stromal cells and their secretome have shown great potential in preclinical models of lung disease, targeting the major pathological features of the disease. Current research and clinical trials are focused on the adult population. For cellular therapies to progress from preclinical studies to use in the clinic, optimal cell type dosage and delivery methods need to be established and confirmed. Direct delivery of these therapies to the lung as aerosols would allow for lower doses with a higher target efficiency whilst avoiding potential effect of systemic delivery. There is a clear need for research to progress into the clinic for the treatment of paediatric respiratory disease. Whilst research in the adult population forms a basis for the paediatric population, varying disease pathology and anatomical differences in paediatric patients means a paediatric-centric approach must be taken. View Full-Text
Keywords: paediatric; cellular therapy; respiratory disease; aerosol delivery; inhalation; stem cells; extracellular vesicles; PARDS; asthma; interstitial lung disease paediatric; cellular therapy; respiratory disease; aerosol delivery; inhalation; stem cells; extracellular vesicles; PARDS; asthma; interstitial lung disease
Show Figures

Figure 1

MDPI and ACS Style

Brennan, L.C.; O’Sullivan, A.; MacLoughlin, R. Cellular Therapy for the Treatment of Paediatric Respiratory Disease. Int. J. Mol. Sci. 2021, 22, 8906. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22168906

AMA Style

Brennan LC, O’Sullivan A, MacLoughlin R. Cellular Therapy for the Treatment of Paediatric Respiratory Disease. International Journal of Molecular Sciences. 2021; 22(16):8906. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22168906

Chicago/Turabian Style

Brennan, Laura C., Andrew O’Sullivan, and Ronan MacLoughlin. 2021. "Cellular Therapy for the Treatment of Paediatric Respiratory Disease" International Journal of Molecular Sciences 22, no. 16: 8906. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22168906

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop